Shire’s Q3 2018 Earnings: Analyst Estimates

Expectations for Shire’s Q3 2018 EPS

Shire (SHPG) is a biotechnology company focused on discovering, developing, and commercializing specialty medicines to treat rare diseases and other specialized conditions. Shire is set to release its third quarter of 2018 earnings on November 1. Wall Street analysts estimate EPS of $3.58 on revenues of $3.82 billion.

Shire’s Q3 2018 Earnings: Analyst Estimates

The above chart compares Shire’s EPS and revenues since the first quarter of 2017 and estimates for the third quarter of 2018.

Revenue estimates for Q3

Shire is expected to report a 3.3% increase in year-over-year revenues to ~$3.82 billion for the third quarter compared to ~$3.7 billion in the third quarter of 2017.

Profitability estimates

Analysts expect Shire’s gross profit margin to increase to 74.1% for the third quarter compared to 72.9% in the third quarter of 2017. Its EBITDA margin is expected to decrease to 41.1% compared to 43.8% in Q3 2017. The decrease might be due to increased operating expenses. Its net adjusted income is expected to decrease to ~$1.1 billion compared to ~$1.16 billion in Q3 2017.

The iShares Nasdaq Biotechnology ETF (IBB) holds 1.6% of its total investments in Shire (SHPG), 2.4% in BioMarin Pharmaceutical (BMRN), 6.9% in Celgene (CELG), and 7.9% in Biogen (BIIB).